Sanofi Backs Out of Revolution Partnership in Latest Cancer Cull
08 Dec 2022
Phase 1Phase 2Phase 3License out/inAcquisition
Chesnot/Getty Images
Sanofi has terminated its global development and commercialization pact with Revolution Medicines, Inc. for Revolution's SHP2 inhibitorSHP2 inhibitor drug candidate, the California-based biotech announced Thursday.
Revolution regains all rights to the investigational SHP2 inhibitorSHP2 inhibitor RMC-4630 for the treatment of patients with certain RAS-addicted cancers.
All commercial proceeds from RMC-4630 will go back to Revolution, and the company will take sole responsibility for decisions made regarding the candidates' research and development. During the first half of 2023, Sanofi and Revolution will work on transitioning all of the pharma giant's rights and responsibilities regarding RMC-4630.
In an e-mail to BioSpace, a Sanofi spokesperson said that the decision to terminate the Revolution partnership follows "a recent portfolio review and prioritization."
After losing a powerhouse partner, Revolution is now estimating its full-year net loss to be between $245 and $265 million, including non-cash stock-based compensations valued from $30 to $35 million.
Still, the oncology-focused biotech is confident that its current cash, cash equivalents and marketable securities can keep it afloat, funding its planned operations through 2024.
Sanofi and Revolution inked their collaboration in 2018. Pledging up to $500 million, Sanofi bought into Revolution's SHP2 program, which aimed to tackle cancer through the RAS-MAP kinase pathway, where the SHP2 enzyme appears to play a role in the development of malignancies. RMC-4630 is an inhibitor of SHP2.
Under the terms of the 2018 deal, Revolution was to take charge of early research and clinical development, while Sanofi was to be responsible for later-stage development activities. Profit was to be shared 50/50.
Revolution expects Sanofi to continue to fulfill its obligations throughout the transition period. This includes reimbursing relevant costs incurred by Revolution throughout the partnership.
Sanofi's Cancer Cull
Recent months have seen a notable thinning of Sanofi's cancer pipeline. In August, amcenestrant, the company's investigational oral selective estrogen receptor degrader, failed to meet its primary endpoint in the Phase III AMEERA-5 trial, forcing the company to terminate all global clinical development for the candidate.
Amcenestrant also flopped its Phase II assessment in the AMEERA-3 study a few months earlier, in March.
At the time, losing amcenestrant left Sanofi with five oncology hopefuls, barring compounds in Phase I studies: the monoclonal antibody alomfilimab, the anti-CD38 Sarclisa (isatuximab-irfc), a non-alpha IL-2 molecule SAR444245, an anti-CEACAM5 ADC tusamitamab ravtansine and SAR442720, the SHP2 and KRAS inhibitor developed under the Revolution collaboration.
In late October, citing lack of efficacy, Sanofi also dropped SAR444245, which it gained when it bought out the San Diego company Synthorx. Sanofi is now down to four mid and late-stage cancer candidates.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.